Skip to main content
An official website of the United States government
Email

Cervical SPOREs

Cervical cancer development is driven by the transforming abilities of the human papillomavirus (HPV). Although the incidence of cervical cancer is fairly low in the United States due to the advent of the "pap" smear test and vaccination, 13,820 new cases and 4,360 deaths are projected in 2024 according to the NCI's Surveillance, Epidemiology, and End Results Program (SEER). The 5-Year relative survival rate is 67.4% (2014-2020). The Johns Hopkins University Cervical SPORE was first funded in 2013, and its major activities are focused on the development of the next generation of novel preventive and therapeutic vaccines to improve treatment outcomes of patients with HPV-associated cervical cancer and its precursor lesions.

Johns Hopkins University Cervical Cancer SPORE

  • Reviewed:

If you would like to reproduce some or all of this content, see Reuse of NCI Information for guidance about copyright and permissions. In the case of permitted digital reproduction, please credit the National Cancer Institute as the source and link to the original NCI product using the original product's title; e.g., “Cervical SPOREs was originally published by the National Cancer Institute.”

Email